Phase I clinical trial - Appareil pulmonaire
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937;(Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a;Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung;Cancer.;As a bispecific antibody capable of engaging the extracellular domains of both EGFR and cMet receptors,;JNJ-61186372 has a unique mechanism of action that has demonstrated preliminary efficacy in an;ongoing Phase 1 study. The unique mechanism of action of JNJ-61186372 suggests potential to improve;clinical outcomes through JNJ-61186372 and EGFR-TKI combination therapy as well. In addition, the;synergistic mechanisms of action of JNJ-61186372 combined with antiEGFR TKI therapy, which targets;both the extracellular ligand binding domain and the intracellular active site, respectively, has the;potential to more potently inhibit the EGFR pathway than either agent alone.